Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why AnaptysBio Shares Rose Nearly 14% on Thursday

TheMotleyFool

0 0

Why AnaptysBio Shares Rose Nearly 14% on ThursdayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

Biotech stocks are often seesaw affairs. Exhibit A: AnaptysBio (NASDAQ: ANAB), which enjoyed a 13.5% rise on Thursday. This nice jump comes mere days after a queasy slide due to the highly discouraging results of a key clinical trial for the company.

AnaptysBio and its investors had high hopes for a pipeline drug called imsidolimab, which the company was developing to treat a rare autoimmune disease called palmoplantar pustulosis (PPP).

Image source: Getty Images.

Source Fool.com

Like: 0

ANAB

Share